Difference between revisions of "Carfilzomib (Kyprolis)"
Jump to navigation
Jump to search
m |
(updated content) |
||
| Line 4: | Line 4: | ||
Route: IV | Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | |||
<br>NDC: NDC 76075-101-01; NDC 76075-0101-01 | <br>NDC: NDC 76075-101-01; NDC 76075-0101-01 | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/kyprolis-carfilzomib-999762 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/kyprolis-carfilzomib-999762 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Multiple myeloma]] | ||
==Patient drug information== | ==Patient drug information== | ||
*Brief patient counseling information is available on [http://kyprolis.com/Content/pdf/PrescribingInformation.pdf#page=21 pages 21-22 of the Carfilzomib (Kyprolis) package insert].<ref name="insert"></ref> | *Brief patient counseling information is available on [http://kyprolis.com/Content/pdf/PrescribingInformation.pdf#page=21 pages 21-22 of the Carfilzomib (Kyprolis) package insert].<ref name="insert"></ref> | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/carfilzomib.aspx Carfilzomib (Kyprolis) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/carfilzomib.aspx Carfilzomib (Kyprolis) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/carfilzomib-patient-drug-information Carfilzomib (Kyprolis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/carfilzomib-patient-drug-information Carfilzomib (Kyprolis) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/carfilzomib-patient-drug-information Carfilzomib (Kyprolis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/carfilzomib-patient-drug-information Carfilzomib (Kyprolis) patient drug information (UpToDate)]</ref> | ||
| Line 19: | Line 22: | ||
Precise Name: carfilzomib (RXCUI 1302966) | Precise Name: carfilzomib (RXCUI 1302966) | ||
| − | CFZ or PR-171 | + | CFZ or PR-171. |
==References== | ==References== | ||
| Line 26: | Line 29: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | |||
[[Category:Proteasome inhibitors]] | [[Category:Proteasome inhibitors]] | ||
| − | |||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 10:49, 11 August 2014
General information
Class/mechanism: Second-generation proteasome inhibitor that interferes with degradation of ubiquitinated proteins by binding irreversibly to the 20S proteasome, which is the proteolytic core particle inside the 26S proteasome. This disrupts normal homeostatic mechanisms, leading to impaired tumor proliferation, apoptosis/cell death.[1][2][3][4][5]
Route: IV
Extravasation: no information
NDC: NDC 76075-101-01; NDC 76075-0101-01
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information is available on pages 21-22 of the Carfilzomib (Kyprolis) package insert.[1]
- Carfilzomib (Kyprolis) patient drug information (Chemocare)[6]
- Carfilzomib (Kyprolis) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 7/20/2012: Received accelerated approval for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy
Also known as
Precise Name: carfilzomib (RXCUI 1302966)
CFZ or PR-171.
References
- ↑ 1.0 1.1 1.2 Carfilzomib (Kyprolis) package insert
- ↑ Carfilzomib (Kyprolis) package insert (locally hosted backup)
- ↑ Kyprolis manufacturer's website
- ↑ Kyprolis 7/20/2012 FDA approval press release
- ↑ Carfilzomib (Kyprolis) manufacturer's clinical development website
- ↑ Carfilzomib (Kyprolis) patient drug information (Chemocare)
- ↑ Carfilzomib (Kyprolis) patient drug information (UpToDate)